Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
cTRL Therapeutics logo — We are simplifying solid tumor cell therapy to unlock the ne...

cTRL Therapeutics

We are simplifying solid tumor cell therapy to unlock the next frontier of cancer therapies.

Founded 2019 United States San Francisco, United States 9 employees Seed Total: $10.00M Biotechnology, Health Care +2

General Information

Company Name cTRL Therapeutics
Founded Year 2019
Location United States San Francisco, United States
Employees 9
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Seed
Business Model B2B, B2B2C
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with cTRL Therapeutics. To contact cTRL Therapeutics, visit ctrl-therapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About cTRL Therapeutics

cTRL Therapeutics, founded in 2019, is at the forefront of revolutionizing cell therapy for treating solid tumors. With a captivating slogan, "We are simplifying solid tumor cell therapy to unlock the next frontier of cancer therapies.", the company showcases its commitment to developing cutting-edge autologous cell therapies. Their strategic focus on collaborative and transparent company culture emphasizes integrity and a drive for excellence.

Operating in the dynamic landscape of Biotechnology, Health Care, Health and Wellness, and Life Sciences, cTRL Therapeutics is headquartered in the United States. The company secured a significant financial foothold with a $10.00M Seed Round investment in April 2023, backed by notable investors like General Catalyst, FACIT, and Intermountain Healthcare. This funding symbolizes strong confidence in the company's potential to transform cancer therapies.

Taxonomy: solid tumor, cell therapy, cancer treatment, autologous cell therapy, oncology, start-up, innovation, medical research, company culture, integrity, excellence, passionate team

Services & Products

Polyclonal cell therapy development
Circulating T cell isolation
Proprietary platform for cell sorting
Solid tumor cancer treatment

Target Customers

Oncologists Cancer treatment centers Biotechnology researchers Patients with solid tumors

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $10.00M 3
General Catalyst FACIT
General Catalyst, FACIT +1
10 Apr 2023

cTRL Therapeutics Alternatives & Competitors

View All Alternatives
cTRL Therapeutics vs
Huasaiboman Medical Cell Biology
Huasaiboman Medical Cell Biology

Pioneering tomorrow's treatments for solid tumors and degenerative diseases through state-of-the-art...

Series A
Biotechnology, Life Sciences
cTRL Therapeutics vs
ONK Therapeutics
ONK Therapeutics Ireland

Pioneering optimally engineered NK cell therapies to cure patients with cancer.

Series A
20 employees
Biotechnology, Health Care
cTRL Therapeutics vs
Tessa Therapeutics Ltd
Tessa Therapeutics Ltd Singapore

A clinical-stage biotech company developing autologous and allogeneic cell therapies for the treatme...

Grant
31 employees
Biotechnology, Health Care
View all alternatives

FAQ About cTRL Therapeutics

We are simplifying solid tumor cell therapy to unlock the next frontier of cancer therapies.
cTRL Therapeutics was founded in 2019.
cTRL Therapeutics is headquartered in San Francisco, United States.
cTRL Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on solid tumor, cell therapy, cancer treatment and autologous cell therapy. Its customers include Oncologists, Cancer treatment centers and Biotechnology researchers.
cTRL Therapeutics has a B2B and B2B2C business model. Its revenue comes from Product Sales and Licensing.
cTRL Therapeutics has approximately 9 employees.
cTRL Therapeutics has completed 1 funding round, raising a total of $10.00M. The latest funding stage is Seed.
cTRL Therapeutics offers: Polyclonal cell therapy development, Circulating T cell isolation, Proprietary platform for cell sorting, Solid tumor cancer treatment.
Top alternatives and competitors to cTRL Therapeutics include Huasaiboman Medical Cell Biology, ONK Therapeutics, Tessa Therapeutics Ltd, Alliance for Cancer Gene Therapy, Gracell Biotechnologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
cTRL Therapeutics and Huasaiboman Medical Cell Biology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for cTRL Therapeutics, https://bouncewatch.com/company/ctrl-therapeutics, updated 19 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes